Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.

OBJECTIVES To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA. METHODS A systematic review of the literature and meta-analysis were performed. We included randomized controlled trials (RCTs) assessing the effect of biotherapies vs placebo on fatigue, in combination with DMARDs. Fatigue was measured using the functional assessment of chronic illness therapy-fatigue (FACIT-F) or short-form 36 (SF-36) vitality scores at baseline and at Week 24. The results were in effect size (ES) for each biotherapy (or class of biotherapy) vs placebo. An ES of <0.5 was considered as small, between 0.5 and 0.8 as moderate and >0.8 as important. RESULTS From the 763 published studies, 10 RCTs were included in the analysis: seven involved IR-DMARD RA and three IR-anti-TNF. Among the 3837 included patients with established RA, 1227 patients were treated with an anti-TNF, 420 with rituximab, 258 with abatacept, 205 with tocilizumab and 1727 received placebo. The overall ESs of all biotherapies vs placebo on fatigue were small (ES = 0.45; 95% CI 0.31, 0.58) as well as for anti-TNFs (ES = 0.36; 95% CI 0.21, 0.51). The ESs were small in IR-DMARD RA (ES = 0.38; 95% CI 0.30, 0.46), similar between anti-TNF and non-anti-TNF agents and moderate in IR-anti-TNF RA (ES = 0.57; 95% CI 0.27, 0.86). CONCLUSION Few studies reported the impact of biotherapies on fatigue. The effect of biotherapies on fatigue in RA is small.

[1]  P. Tugwell,et al.  Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[2]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[3]  M. Genovese,et al.  Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[4]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[5]  M. Calnan,et al.  Patient perspective of measuring treatment efficacy: The rheumatoid arthritis patient priorities for pharmacologic interventions outcomes , 2010, Arthritis care & research.

[6]  V. Strand,et al.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Arthritis and rheumatism.

[7]  G. Bleijenberg,et al.  Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. , 2010, Rheumatology.

[8]  P. Tugwell,et al.  Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[9]  M. Dougados,et al.  Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review , 2008, Annals of the rheumatic diseases.

[10]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[11]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[12]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[13]  V. Strand,et al.  Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial , 2009, Arthritis research & therapy.

[14]  M. Dougados,et al.  Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy , 2007, Annals of the rheumatic diseases.

[15]  F. Wolfe,et al.  The prevalence and meaning of fatigue in rheumatic disease. , 1996, The Journal of rheumatology.

[16]  J. Ware,et al.  Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. , 2006, The Journal of rheumatology.

[17]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[18]  F. Bethoux,et al.  Sensitivity to change of the Quebec Back Pain Disability Scale and the Dallas Pain Questionnaire. , 2010, Annals of physical and rehabilitation medicine.

[19]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[20]  J. Kirwan,et al.  Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. , 2007, Arthritis and rheumatism.

[21]  T. Kvien,et al.  The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. , 2005, Arthritis and rheumatism.

[22]  Alex J. Sutton,et al.  The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis , 2010 .

[23]  D. Revicki,et al.  Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. , 2008, The Journal of rheumatology.

[24]  V. Strand,et al.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.

[25]  H. Genant,et al.  Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors , 2009, Annals of the rheumatic diseases.

[26]  B. Belza,et al.  Correlates of Fatigue in Older Adults with Rheumatoid Arthritis , 1993, Nursing research.

[27]  D. Cella,et al.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[28]  Mahboob Rahman,et al.  Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial , 2009, The Lancet.

[29]  J. Dupond.  Fatigue in patients with rheumatic diseases. , 2011, Joint, bone, spine : revue du rhumatisme.

[30]  I. Belan,et al.  Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. , 2006, Journal of advanced nursing.

[31]  M. Thyberg,et al.  Factors related to fatigue in women and men with early rheumatoid arthritis: the Swedish TIRA study. , 2009, Journal of rehabilitation medicine.

[32]  John E. Ware,et al.  SF-36 Health Survey Update , 2000, Spine.

[33]  P. Tugwell,et al.  Patient Perspective on Outcomes in Rheumatology — A Position Paper for OMERACT 9 , 2009, The Journal of Rheumatology.

[34]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[35]  E. Choy,et al.  Fatigue in rheumatoid arthritis reflects pain, not disease activity. , 2006, Rheumatology.

[36]  Mahboob Rahman,et al.  Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study , 2008, Annals of the rheumatic diseases.

[37]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[38]  M. Broder,et al.  Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. , 2008, Arthritis and rheumatism.

[39]  D. Cella,et al.  Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.